Psoriasis Vulgaris
200
8
9
140
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
52 trials with published results (26%)
Research Maturity
140 completed trials (70% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.5%
7 terminated out of 200 trials
95.2%
+8.7% vs benchmark
27%
53 trials in Phase 3/4
37%
52 of 140 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 140 completed trials
Clinical Trials (200)
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
Efficacy of Topical Metformin in Psoriasis Vulgaris
Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
Topical Diacerein in Psoriasis Vulgaris
Topical SGX302 for Mild-to-Moderate Psoriasis
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis
Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
An Explorative Psoriasis Biomarker Study
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
A Pilot Study to Explore the Role of Gut Flora in Psoriasis